Ocular FIP treatment guidance points to higher-dose antiviral care

Ocular FIP is emerging as one of the clearest examples of how feline infectious peritonitis treatment is moving from desperation medicine toward protocol-driven care. Recent veterinary discussion, including VetGirl’s podcast coverage, reflects a broader shift in the literature: cats with ocular involvement can respond to antiviral therapy, but they often need higher-intensity treatment plans than cats with less complicated forms of FIP. That matters because ocular disease is not rare in dry FIP, can occasionally be the dominant presentation, and may be the first visible clue to a systemic infection that otherwise remains diagnostically frustrating. (pmc.ncbi.nlm.nih.gov)

That’s a meaningful change from just a few years ago, when U.S. veterinarians had little formal access to treatment and many pet parents were pushed toward unregulated online markets. In May 2024, the FDA said it did not intend to enforce approval requirements for compounded GS-441524 prescribed by veterinarians for specific feline FIP patients under Guidance for Industry #256, and compounded oral GS-441524 became available in the U.S. on June 1, 2024 through Stokes Pharmacy in collaboration with Bova. Cornell called that availability a major step forward for a disease that had long been considered almost uniformly fatal. (fda.gov)

The ocular-specific evidence is still limited, but it’s getting stronger. In a 20-cat observational case series published in 2025, 17 cats initially received injectable remdesivir, while three received oral GS-441524 alone. Most cats were treated at higher dose ranges, with remdesivir commonly dosed at 15 to 20 mg/kg and oral GS-441524 often given at 15 to 22 mg/kg. The authors reported that ocular signs improved in many cats during treatment, and one cat with panuveitis had complete resolution on antiviral therapy alone during the treatment course. VetGirl’s review of the paper also underscored a practical point for generalists: ocular FIP may show up as anterior uveitis, keratic precipitates, iris color change, dyscoria, hyphema, hypopyon, fibrinous exudate, retinal hemorrhage, tapetal or non-tapetal lesions, vascular tortuosity, retinal detachment, or perivascular cuffing, sometimes in just one eye at first. (pmc.ncbi.nlm.nih.gov)

That dosing pattern aligns with broader expert commentary. Clinician’s Brief noted that cats with neurologic and ocular FIP appear to require larger doses because inflammation and subsequent healing of the blood-brain and blood-ocular barriers can affect drug penetration. The 2025 ABCD FIP guideline also reflects this more intensive approach, citing protocols that escalate dosing when neurologic or ocular signs are present and summarizing studies in which those signs resolved in nearly all surviving cats. Separate VetGirl discussion on dosing and duration has pushed the conversation a step further, highlighting interest in higher-dose induction therapy up front to reduce viral burden faster, particularly in hard-to-penetrate tissues such as the eye and central nervous system. (cliniciansbrief.com)

The wider FIP literature adds some caution. A 2024 systematic review of GS-441524 studies found overall outcomes were strong, but cats with neurologic and/or ocular signs had lower combined success rates than the general FIP population. That doesn’t mean ocular FIP is untreatable, only that it remains a higher-risk subgroup where case selection, dosing, follow-up, and client expectations matter more. It also reinforces a point made in recent podcast discussions: cats often look dramatically better within the first week of antiviral therapy, but early clinical improvement does not necessarily mean the virus has been fully cleared. (pmc.ncbi.nlm.nih.gov)

For veterinary teams, the practical takeaway is that ocular FIP now sits in a more actionable middle ground: urgent, serious, but increasingly treatable. That changes the exam-room conversation. Instead of framing ocular lesions, uveitis, or panuveitis in a suspected FIP cat as purely terminal findings, clinicians can discuss antiviral options, referral considerations, serial ophthalmic assessment, and the likelihood that treatment may need to be more aggressive than standard protocols for uncomplicated cases. It also raises pharmacy, compliance, and monitoring questions, especially as compounded products, extra-label remdesivir use, and alternative antivirals such as molnupiravir continue to enter practice discussions. Recent clinical education has also emphasized using more than appearance alone to guide treatment decisions, with growing interest in objective markers such as serum amyloid A, alpha-1 acid glycoprotein, and albumin:globulin ratio trends when deciding whether therapy can safely be stopped. (vet.cornell.edu)

Industry reaction has largely centered on access and legitimacy. Professional and pharmacy sources have framed legal compounded GS-441524 availability as a way to move care away from black-market channels and back into veterinary supervision. That’s especially relevant in ocular FIP, where dose adjustments and treatment response may need closer oversight than pet parents can safely manage on their own. Broader practice-oriented discussions have also stressed that FIP remains a presumptive diagnosis in many real-world cases, making careful synthesis of signalment, clinicopathologic changes, effusion analysis, imaging, and ocular findings especially important before and during treatment. (aaha.org)

What to watch: The next phase is likely to focus on standardizing protocols, particularly around when to start with remdesivir versus oral GS-441524, how high to dose ocular cases, whether adjunctive ophthalmic therapy changes outcomes, and when alternatives such as molnupiravir should be used in first-line or rescue settings. Just as important, clinicians will be watching for better stopping criteria, including whether acute phase proteins and albumin:globulin trends can help shorten treatment safely in selected cats without increasing relapse risk. For now, ocular FIP treatment is becoming more evidence-based, but it’s not yet settled science. (pmc.ncbi.nlm.nih.gov)